

Revised 4/1/2009

**CURRICULUM VITAE
DANIEL W. LIN, MD**

PERSONAL DATA

Office Address: Department of Urology
University of Washington Medical Center
1959 NE Pacific Street, Box 356510
Seattle, Washington 98195
206-667-1342

Email address: dlin@u.washington.edu

Birthdate: August 16, 1967

Place of Birth: Cleveland, Ohio

Citizenship: U.S.A.

EDUCATION

09/85 – 06/89 Stanford University
Stanford, California
B.S., Biology, 1989

08/90 – 05/94 Vanderbilt University School of Medicine
Nashville, Tennessee
M.D., 1994

POSTGRADUATE TRAINING

07/94 – 06/95 Internship, Department of Surgery
University of Washington School of Medicine
Seattle, Washington

07/95 – 12/95 Residency, Department of Surgery
University of Washington School of Medicine
Seattle, Washington

01/96 – 06/99 Residency, Department of Urology
University of Washington School of Medicine
Seattle, Washington

07/99 – 06/00 Chief Residency, Department of Urology
University of Washington School of Medicine
Seattle, Washington

07/00 – 8/01 Fellowship, Urologic Oncology
Department of Urology
Memorial Sloan-Kettering Cancer Center
New York, New York

POSTGRADUATE RESEARCH TRAINING

- 07/96 – 06/97 Mentor/Lab: Robert Vessella, PhD
GU Cancer Research Laboratory
Department of Urology, University of Washington
Funding: Intramural
Effort: 100%
- 09/01 – 08/03 Mentor/Lab: Peter Nelson, MD
Division of Human Biology
Fred Hutchinson Cancer Research Center
Funding: American Foundation of Urologic Disease (AFUD) and National
 Institutes of Health/National Institute of Diabetes and Digestive and
 Kidney Diseases (NIH/NIDDK)
Effort: 80%
- 09/03 – 08/08 Mentor/Lab: Alan Kristal, PhD and Peter Nelson, MD
Divisions of Public Health Science and Human Biology
Fred Hutchinson Cancer Research Center
Funding: NIH/NIDDK
Effort: 50%

ACADEMIC APPOINTMENTS

- 9/01 – 10/03 Acting Assistant Professor, Department of Urology, University of
Washington School of Medicine, Seattle, Washington
- 4/02 – 8/06 Associate in Human Biology, Division of Human Biology, Fred
Hutchinson Cancer Research Center, Seattle, Washington
- 10/03 – 07/08 Assistant Professor, Department of Urology, University of
Washington School of Medicine, Seattle, Washington
- 3/04 – 11/06 Affiliate in Public Health Sciences, Division of Public Health
Sciences, Fred Hutchinson Cancer Research Center, Seattle,
Washington
- 11/06 – present Assistant Member (Joint), Cancer Prevention Program, Division of
Public Health Sciences, Fred Hutchinson Cancer Research Center,
Seattle, Washington
- 7/08 – present Associate Professor, Department of Urology, University of
Washington School of Medicine, Seattle, Washington
- 9/08 – present Chief, Division of Urologic Oncology, Department of Urology,
University of Washington School of Medicine, Seattle,
Washington
- 1/09 – present Director, Urologic Oncology Fellowship Program, Department of
Urology, University of Washington School of Medicine, Seattle,
Washington

HOSPITAL APPOINTMENTS

9/01 – present Clinical Staff, Veteran’s Affairs Puget Sound Health Care System,
Seattle Division, Seattle, WA

9/01 – present Clinical Staff, Harborview Medical Center, Seattle, WA

12/03 – present Associate Clinical Staff, Seattle Cancer Care Alliance, Seattle, WA

11/06 – present Clinical Staff, Children’s Hospital and Regional Medical Center,
Seattle, WA

HONORS

06/89 Undergraduate Teaching Award, Department of Biological Science,
Stanford University

06/94 Alpha Omega Alpha (AOA), Vanderbilt University Medical School

12/97 Best Resident Paper, Northwest Urological Society

06/98 Warren H. Chapman Resident Research Award, University of Washington

10/98 James L. Goebel Grand Prize Poster, Western Section American
Urological Association

10/98 Earl F. Nation Resident Scholarship, Western Section American
Urological Association

12/98 Best Resident Paper, Northwest Urological Society

06/00 Pfizer Scholar in Urology, University of Washington

05/04 American Urological Association/Yamanouchi First Prize Poster

01/06 Service Excellence Award, University of Washington

10/06 Joseph F. McCarthy/ACMI Second Prize Essay, Western Section
American Urological Association

05/07 Society of Basic Urologic Research Young Investigator Award,
Society of Basic Urologic Research

01/08 American Urologic Association/European Association of Urology
Academic Scholar, AUA/EAU

06/08 Julian S. Ansell Faculty Teaching Award, University of Washington

04/09 Best Reviewer 2008, Journal of Urology

04/09 Society of Urologic Oncology Young Investigator Award, Society of
Urologic Oncology

BOARD CERTIFICATION

2/03 American Board of Urology

LICENSURE

1997 - present Washington #MD0003550
2000 - 2002 New York #217848

PROFESSIONAL ORGANIZATIONS

American Urological Association, 1996 – present
American Medical Association, 1996 – 2006

Southwest Oncology Group (SWOG), 2001 – present
Western Section American Urological Association, 2003 – present
Washington State Urological Society, 2003 – present
Society of Urologic Oncology, 2004 – present
Northwest Urologic Society, 2004 – present
Society of Basic Urologic Research, 2006 – present
Urological Research Society, 2007 – present

COMMITTEES

Local and University

Steering Committee, Prostate Cancer SPORE Database project, University of Washington/Fred Hutchinson Cancer Research Center, 2002 – present
Search Committee, Department of Surgery, Division of Surgical Oncology, Veterans Affairs Puget Sound Health Care System, 2004 – 2005
Data Safety Monitoring Board, Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Carcinoma: a Phase II Trial, Fred Hutchinson Cancer Research Center, ID #NCT00136526, 2005 – 2007
IPCR Caisis Fiscal Working Group, University of Washington/Fred Hutchinson Cancer Research Center, 2006 – present
Graduate Thesis Committee, PhD Candidate: Jeannette Schenk, 2007 – 2008
Scientific Review and Evaluations Committee, Veterans Affairs Puget Sound Health Care System, 2007- present
Executive Board, Washington State Urology Society, 2007 - present

National

Steering Committee, Young Urologic Oncologist Section, Society of Urologic Oncology, 2003 – 2007
SUO Fellowship Committee, Society of Urologic Oncology, 2007 – present
Prostate Cancer Foundation (PCF) Peer Review Committee, 2008 – present
SUO Clinical Trials Consortium (CTC) Board of Directors, Society of Urologic Oncology, 2008 – present
Study Section, Prostate Cancer Clinical Trial Award (CTA) Study Section, DOD Congressionally Directed Medical Research Programs, 2008
Abstract Review Committee, Team Leader, American Urological Association, 2008
International Exchange Review Committee, American Urological Association, 2008 – present

JOURNAL RESPONSIBILITIES

Ad hoc review

Journal of Urology, 2002 – present
Asian Journal of Andrology, 2003 – present
Urologic Oncology, 2005 – present
British Journal of Urology International, 2006 – present
Cancer, 2006 – present
European Urology, 2006 – present
Cancer Research, 2006 – present
Journal of Cellular and Molecular Medicine, 2007 – present
Urology, 2008 – present
Prostate, 2008 – present
World Journal of Urology, 2008 – present

Review Committee

Clinical Research Survey Section, Urologic Oncology, 2007 – present

Associate Editor

Advances in Urology, 2006 – present

Journal of Medical Case Reports, 2007 – present

UroToday International Journal, 2008 – present

TEACHING RESPONSIBILITIES

Resident Education

Urology Teaching Conference, Department of Urology, University of Washington:

January 2003, Upper Tract Transitional Cell Carcinoma

April 2003, Tumors of the Urinary Bladder

October 2004, Management and Follow-up of Testis Cancer

March 2005, Urothelial Carcinoma: Recent Advances and Treatment Options

July 2005, Prostate Cancer: Natural History of Untreated Prostate Cancer and Expectant Management

March 2006, Management of Clinical Stage I Nonseminomatous Germ Cell Tumor

March 2007, Management and Prognosis in Muscle-Invasive and Advanced Bladder Cancer

June 2007, Testicular Cancer: Epidemiology, Presentation, and Management

July 2007, Prostate Cancer Update 2007

April 2008, Staging and Treatment Strategies in Adult Germ Cell Tumors

October 2008, Orthotopic Urinary Diversion

Medical School Student Education

Lecturer, Human Biology 562, Genitourinary Tumors, University of Washington School of Medicine, April 2003.

Urology Course Director and Lecturer, Human Biology 562, University of Washington School of Medicine, January 2004 – November 2005

Lecturer, Human Biology 562, Genitourinary Tumors, University of Washington School of Medicine, December 2006.

Lecturer, Human Biology 562, Genitourinary Tumors, University of Washington School of Medicine, November 2007.

Lecturer, Human Biology 562, Genitourinary Tumors, University of Washington School of Medicine, November 2008.

Research Project Mentoring

Emily Williams, University of Washington Medical School student, 2001-2004, Reverse transcriptase-polymerase chain reaction (RT-PCR) in prostate cancer staging

Jonathon Wright, MD, Urology resident, 2003- 2007, Predictors of outcome in advance prostate cancer; Rare genitourinary tumors: a SEER analysis.

Philip Kezele, PhD, Post-doctoral scientist, 2003-2004, Genomic Analysis of *In Vivo* Drug Effects in the Prostate

Rajen Doshi, MD, Urologic Oncology Fellow, 2004-2005, Surgical management of locally, advanced and hormone refractory prostate cancer

Hong Gee Sim, MD, Urologic Oncology Fellow, 2005-2007, Outcomes analysis in patients following radical prostatectomy for clinically localized prostate cancer

Michael Risk, MD PhD, Urology Resident, 2006-2007, Gene expression and field effect in human prostate cancer
Jonathon Wright, MD, Urologic Oncology Fellow, 2007 – present, multiple projects on genitourinary cancer outcomes
Todd Morgan, MD, Urology Resident, 2007-present, Defining biochemical recurrence after radical prostatectomy

RESEARCH FUNDING

ACTIVE

VA Cooperative Studies Program Protocol #553 (co-P.I. Montgomery, Lin)

Department of Veteran's Affairs

5/02/05 - 5/01/10

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma: A Phase III Randomized Study

The major goal of this project is to evaluate the efficacy of adjuvant chemotherapy to prevent progression in patients at high risk for relapse after radical prostatectomy for clinically localized prostate cancer. The co-investigators are the national P.I.'s of this Phase III clinical trial administered through the VA Cooperative Studies Program.

Role: Co-PI

DAMD PC061307 (PI: B.Lin)

12/01/06 – 11/30/09

Department of Defense

\$375,000

Prostate Specific or Enriched Genes as Composite Biomarkers for Prostate Cancer

The major goal of this project is to examine multiple, novel prostate-enriched and -secreted proteins such as WDR19, NDRG1, and other current prostate cancer biomarkers to increase the sensitivity and specificity in prostate cancer early detection and stratification.

Role: Co-PI

P50 CA 97186 (PI: Nelson)

5/01/07 – 6/30/12

NIH/NCI

\$708,062

Genetic Susceptibility in Clinically Aggressive Prostate Cancer: Pacific Northwest Prostate Cancer SPORE (Project 1)

Project 1 will evaluate whether germline genetic polymorphisms in selected genes predict prostate cancer progression/mortality in a population-based cohort of prostate cancer patients.

Role: Co-Project Leader

Active Surveillance Trial and Biorepository (PI: Lin)

10/01/07 – 01/31/10

Canary Foundation

\$320,263

Prostate Active Surveillance Trial

The primary objective of this multi-institutional study is to discover and confirm biomarkers that predict aggressive disease in a prospective cohort of men on active surveillance. Dr. Lin serves as national PI of the clinical trial.

Role: PI

Prostate Cancer Foundation Challenge Award

7/01/08 – 6/30/09

Prostate Cancer Foundation (co-PIs: Balk and Nelson)

\$475,000

Synergistic Targeting of Androgen Receptor and Androgen Metabolism in Prostate Cancer

This primary objectives of this project are to determine whether more aggressive neoadjuvant suppression of intraprostatic androgen levels decreases AR function and improves pathological responses, to determine whether agents that further suppress androgen synthesis or impair AR

function by other mechanisms can suppress AR activity in CRPC, and to assess the activity of novel drugs and combination therapies targeting AR in preclinical xenograft models representing a spectrum of CSPC and CRPC.

Role: Co-investigator

PENDING

R01 CA 131255 (Priority Score 132, 7.9th percentile) 12/01/08 – 11/30/12
NIH/NCI (PI: Lin) \$1,648,219

In Vivo Molecular Effects of Sulforaphane Supplementation on Normal Human Prostate

The goal of this project is to use an *in vivo* human intervention model to evaluate the mechanisms underlying the associations of sulforaphane and *Brassica* vegetables with reduced prostate cancer risk.

Role: PI

SUBMITTED

VA Merit (no number assigned) 10/01/09 – 09/30/13
VA HSR&D (PI: Zeliadt) \$855,950

Information Support Tools for Managing Follow up of Elevated PSA Values

The goals of this project are to characterize follow-up care and existing decision support tools, to demonstrate the feasibility of implementing point-of-care tools, and to use a systematic expert panel approach to formulate revisions and refinements to current decision tools.

Role: Co-investigator

COMPLETED

American Foundation for Urologic Disease Physician Scholar Award (PI: Lin)

American Foundation for Urologic Disease 7/01/02 - 6/30/04
\$60,000

Expression and Characterization of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1) in Benign and Malignant Prostate Epithelium

The major goals of this project are to characterize the expression and function of the androgen-regulated gene, PSDR1, in both benign and malignant human prostate tissue.

Role: PI

P50 CA 97186 (PI: Lange) 9/19/02 – 4/30/07
NIH/NCI \$667,416

Molecular Predictors of Prostate Cancer Progression & Mortality: Pacific Northwest Prostate Cancer SPORE (Project 1)

Project 1 will evaluate whether germline genetic polymorphisms in selected genes predict prostate cancer progression/mortality in a population-based cohort of prostate cancer patients.

Role: Co-Project Leader

P50 CA 97186 (PI: Lange) 3/01/05 – 2/28/06
NIH/NCI \$50,000

Serum and Tissue Expression of the Immune Stimulatory Molecule as a Biomarker for Prostate Cancer (Pilot Project for Pacific Northwest Prostate Cancer SPORE)

This pilot Project will determine whether MIC can be used as biomarker to predict the progression or detection of prostate cancer

Role: Co-PI

K23 DK 65083-01 (PI: Lin) 9/15/03 – 8/31/08
NIH/NIDDK \$587,375

In Vivo Molecular Effects of Prostatic COX-2 Inhibition

The major goals of this project are to examine the effects of systemic COX-2 inhibition on *in vivo* human prostate biology with particular attention to changes in cell cycle and DNA damage.

Role: PI

Veterans Affairs Award SHP 08-165 (PI: Zeliadt) 06/01/08 – 12/31/08
VA Health Services Research and Development \$114,800

Study to Assess Gaps in Follow-up for Suspicious PSA Tests

This study will evaluate quality of care for abnormal PSA results. The goal is to develop measures of quality that can be evaluated broadly in the VA in order to reduce inappropriate or poor quality care.

Role: Co-investigator

BIBLIOGRAPHY

MANUSCRIPTS IN REFERRED JOURNALS

1. Koch MO, Brandell RA, **Lin D**, Smith JA: The Effect of Sequential Compression Devices on Intraoperative Blood Loss During Radical Prostatectomy. *Journal of Urology* 152: 1178-9, 1994.
2. **Lin DW**, Gold MH, Ransom S, Ellis WJ, Brawer MK: Transition Zone PSA Density: Lack of Utility in Prediction of Prostatic Carcinoma. *Journal of Urology* 160: 77-82, 1998.
3. **Lin DW**, Noteboom JL, Ellis WJ, Blumenstein B, Lange PH, Vessella RL: Serum Percent Free Prostate-Specific Antigen (f-PSA) in Metastatic Prostate Cancer. *Urology* 52: 366-71, 1998.
4. Kuhr CS, **Lin DW**, Marsh CL: Urologic Complications of Pancreas Transplantation. *Contemporary Urology* 10: 76-84, 1998.
5. Moore MC, **Lin DW**, Colburn CA, Goldstein RE, Neal DW, Cherrington AD: Insulin- and Glucagon-Independent Effects of Calcitonin Gene-Related Peptide in the Conscious Dog. *Metabolism* 48: 603-610, 1999.
6. Brawer MK, **Lin DW**, Williford W, Lepor H: The Effect of Finasteride and/or Terazosin on Serum PSA: The Results of the VA Cooperative #359 Trial. *Prostate* 39: 234-239, 1999.
7. **Lin DW**, Thorning DR, Krieger JN: Primary Penile Lymphoma: Diagnostic Difficulties and Management Options. *Urology* 54: 366, 1999.
8. **Lin DW**, Kuhr CS, Marsh CL: Endoscopic Treatment of Bladder Outlet Obstruction in Men Following Pancreas Transplant. *Journal of Urology* 162: 335-338, 1999.
9. **Lin DW**, Bush WH, Mayo ME: Endoscopic Management of Ureteroenteric Strictures: Efficacy of Acucise Incision. *Journal of Urology* 162: 696-698, 1999.

10. **Lin DW**, Santucci R, Mayo ME, Lange PH, Mitchell MO: Urodynamic Evaluation and Long-term Results of the Orthotopic Gastric Neobladders in Men. *Journal of Urology* 164: 356-359, 2000.
11. Swanson KR, True LD, **Lin DW**, Buhler KR, Vessella R, Murray JD: A quantitative model for the dynamics of serum prostate-specific antigen as a marker for cancerous growth: an explanation for a medical anomaly. *American Journal of Pathology* 158: 2195-9, 2001.
12. Kedishvili NY, Chumakova OV, Chetyrkin SV, Belyaeva OV, Lapshina EA, **Lin DW**, Matsumura M, Nelson PS: Evidence that the Human Gene for Prostate Short-chain Dehydrogenase/Reductase (PSDR1) Encodes a Novel Retinal Reductase (RalR1). *Journal of Biological Chemistry* 277: 28909-28915, 2002.
13. **Lin DW**, Herr HW, Dalbagni G: Value of Urethral Wash after Radical Cystectomy. *Journal of Urology* 169: 961-3, 2003.
14. **Lin DW** and Nelson PS: The Role of COX-2 Inhibition for the Prevention and Treatment of Prostate Carcinoma. *Clinical Prostate Cancer* 2: 119-126, 2003.
15. Zecha G, **Lin DW**, Montgomery RB: The increasing role of CAM in prostate cancer. *JAAPA* 17: 37-44, 2004.
16. Kurek R, Nunez G, Tselis N, Konrad L, Martin T, Roeddiger S, Aumuller G, Zamboglou N, **Lin DW**, Tunn UW, Renneberg H: Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. *Clinical Cancer Research* 10:5808-14, 2004.
17. Gaylis FD, **Lin DW**, Ignatoff JW, Amling CL, Tutron RF, Cosgrove DJ: Prostate Cancer in Men Using Testosterone Supplementation. *Journal of Urology* 174: 534-8, 2005.
18. Wright JL, **Lin DW**, Dewan P, and Montgomery RB: Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. *International Journal of Urology* 12: 1012-3, 2005.
19. Page ST, Plymate SR, Bremner WJ, Matsumoto AM, Hell DL, **Lin DW**, Amory JK, Nelson PS, Wu JD: Effect of Medical Castration on CD4+CD24+ T cells, CD8+ T-cell IFN-(gamma) Expression, and NK Cells: A Physiological Role of Testosterone and/or its Metabolites. *Am J Physiol Endocrinol Metab* 290: 856-63, 2006.
20. Wright JL, Porter MP, Li C, Lange PH, **Lin DW**: Differences in Survival Among Patients with Urachal and Non-Urachal Adenocarcinomas of the Bladder. *Cancer* 107: 721-8, 2006.
21. Walsh TJ, **Lin DW**, Grady RW, Porter MP, and Weiss NS: The Incidence of Testicular Germ Cell Tumors in U.S. Children: the SEER Program Experience 1973-2000. *Urology* 68: 402-5, 2006.

22. **Lin DW**, Coleman IM, Hawley S, Dumpit R, Gifford D, Kezele P, Hung H, Knudsen BS, Kristal AR, and Nelson PS: The Influence of Surgical Manipulation on Prostate Gene Expression: Implications for Molecular Correlates of Treatment Effects and Disease Prognosis. *Journal of Clinical Oncology* 24: 3763-70, 2006.
23. Agalliu I, **Lin DW**, Salinas CA, Iwasaki LM, Feng Z, and Stanford JL: Polymorphisms in the Glutathione S-Transferase M₁, T₁, and P₁ Genes and Prostate Cancer Prognosis. *Prostate* 66: 1535-41, 2006.
24. True L, Coleman I, Hawley S, Huang A, Gifford D, Coleman R, Beer T, Gelman E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella, **Lin DW**, Hood L, and Nelson PS: A Molecular Correlate to the Gleason Grading System for Prostate Adenocarcinoma. *Proceedings of the National Academy of Sciences* 103: 10991-6, 2006.
25. Porter MP and **Lin DW**: Trends in Renal Cancer Surgery in the United States and Patient and Provider Characteristics Associated with Partial Nephrectomy, *Urologic Oncology*, 25: 298-302, 2007.
26. Page ST, **Lin DW**, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, and Bremner WJ: Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men. *J Clin Endocrinol Metab* 91: 3850-6, 2006.
27. Swartz MA, Porter MP, **Lin DW**, and Weiss NS: Incidence of Primary Urethral Carcinoma in the United States, *Urology* 68: 1164-8, 2006.
28. Gong Z, Agalliu I, **Lin DW**, Stanford JL, and Kristal AR: Obesity is Associated with Increased Risks of Prostate Cancer Progression and Death Following Initial Cancer Diagnosis in Middle-Aged Men, *Cancer* 109: 1192-1202, 2007.
29. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, **Lin DW**, Zelefsky MJ, Forman JD, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, and Pollack A: Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer after Radical Prostatectomy. *Journal of Clinical Oncology* 25: 2035-41, 2007.
30. Mostaghel EA, Page ST, **Lin DW**, Fazli L, Coleman IM, True LD, Knudsen BS, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, and Nelson PS: Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist Following Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer. *Cancer Research* 67: 5033-41, 2007.
31. Black PC, Wright JL, Brown GA, Gomez JA, Porter MP, Kamat AM, Dinney CPN, and **Lin DW**: Differences in Survival Between Patients with Sarcomatoid Carcinoma, Carcinosarcoma, and Transitional Cell Carcinoma of the Bladder. *Journal of Urology* 178: 2302-6, 2007.
32. Agalliu I, Weiss NS, **Lin DW**, and Stanford JL: Prostate Cancer Mortality in Relation to Screening by Prostate-Specific Antigen Testing and Digital Rectal Examination: A Population-Based Study in Middle-Aged Men. *Cancer Causes and Control* 18: 931-7, 2007.

33. Montgomery RB, Nelson PS, **Lin DW**, Ryan CW, Garzotto M, and Beer TM: Diethylstilbestrol and Docetaxel: a Phase III Study of Tubulin Active Agents in Patients with Metastatic, Androgen Independent Prostate Cancer. *Cancer* 110: 996-1002, 2007.
34. **Lin DW**, Neuhouser ML, Schenk JM, Coleman IM, Hawley S, Gifford D, Hung H, Knudsen BS, Nelson PS, and Kristal AR: Low-Fat, Low-Glycemic Load Diet and Gene Expression in Human Prostate Epithelium: a Feasibility Study of Using cDNA Microarrays to Assess the Response to Dietary Intervention in Target Tissues. *Cancer Epidemiology, Biomarkers and Prevention* 16: 2150-4, 2007.
35. Wright JL, **Lin DW**, Cowan JE, Carroll PR, and Litwin MS: Quality of Life in Young Men after Radical Prostatectomy: Results from CaPSURE, *Prostate Cancer and Prostatic Diseases* 11: 67-73, 2008.
36. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Matin S, Kamat A, Pisters LL, **Lin DW**, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Blyer A, Sanders WH, Clifford JL, Parnes HL, and Lippman SM: Phase III Prevention Trial of Fenretinide in Patients with Resected Non-Muscle-Invasive Bladder Cancer, *Clinical Cancer Research* 14: 224-9, 2008.
37. Gong Z, Agalliu I, **Lin DW**, Stanford JL, and Kristal AR: Cigarette Smoking and Prostate Cancer-Specific Mortality Following Diagnosis in Middle-Aged Men. *Cancer Causes and Control* 19: 25-31, 2008.
38. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, **Lin DW**, Malik G, Oelschlager D, Partin A, Randolph T, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, and Semmes, J: SELDI-TOF-MS Whole Serum Proteomic Profiling With IMAC Surface Does Not Reliably Detect Prostate Cancer. *Clinical Chemistry* 54:53-60, 2008.
39. Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, and **Lin DW**: Tertiary Gleason Pattern 5 in Gleason 7 Prostate Cancer Predicts Pathologic Parameters and Biochemical Recurrence. *Journal of Urology* 179: 1775-9, 2008.
40. Wright JL, **Lin DW**, and Porter MP: The Association Between Extent of Lymphadenectomy and Survival Among Patients with Lymph Node Metastases Undergoing Radical Cystectomy. *Cancer* 112: 2401-8, 2008.
41. Montgomery RB, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S, Kelly W, Basler J, Ringer R, Yu W, Whittemore A, and **Lin DW**: VA Cooperative Studies Program study #553: Chemotherapy after Prostatectomy (CAP), a Phase III Randomized Study of Prostatectomy vs. Prostatectomy with Adjuvant Docetaxel for Patients with High Risk, Localized Prostate Cancer. *Urology* 72: 474-80, 2008.
42. Wright JL, Morgan TM, and **Lin DW**: Scrotal cancer in the United States over the past 30 years: data from the Surveillance, Epidemiology and End Results (SEER) cancer registry. *Urology* 72: 1139-43, 2008.
43. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, **Lin DW**, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Stephenson AJ, Liauw SL, Scardino PT, Kestin LL, DeWeese

- TL, and Pollack A: A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. *Urology* 72: 1298-302, 2008.
44. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson E, Noteboom J, O'Briant KC, Allen A, **Lin DW**, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, and Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. *Proceedings of the National Academy of Sciences*, 105:10513-8, 2008.
 45. Kristal AR, Song YJ, Schenk JM, Arnold KB, Neuhaus ML, Goodman P, **Lin DW**, Stanczyk FZ, Thompson IM: Serum Steroid and Sex Hormone Binding Globulin Concentrations and the Risk of Incident Benign Prostatic Hyperplasia (BPH): Results from the Prostate Cancer Prevention Trial. *American Journal of Epidemiology* 168: 1416-24, 2008.
 46. Salinas CA, Kooopmeiners, JS, Kwon E, Fitzgerald L, **Lin DW**, Ostrander EA, Feng Z, and Stanford JL: Clinical Utility of Five Genetic Variants for Predicting Prostate Cancer Risk and Mortality. *Prostate* 69:363-72, 2009.
 47. Wu JD, **Lin DW**, Page ST, Lundgren AD, True LD, and Plymate SR: Evidence of DNA Damage Response in the Prostate of Men Referred for Prostate Biopsy. *Translational Oncology* 2:39-45, 2009.
 48. Morgan TM, Lange PH, Porter MP, **Lin DW**, Ellis WJ, Gallaher I, and Vessella RL: Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence. *Clinical Cancer Research*, 15:677-83, 2009.
 49. Schenk JM, Neuhaus ML, **Lin DW**, and Kristal AR: A dietary intervention to elicit rapid and complex dietary changes for studies investigating the effects of diet on tissues collected during invasive surgical procedures. *Journal of the American Dietetic Association* 109:459-63, 2009.
 50. **Lin DW**, Wallner KE, Ellis WJ, Lange PH, and True LD: Inter-Observer Variability and Inaccuracy of Estimated Percentage of Prostate Cancer in Prostate Needle Biopsy Cores. Submitted to *Urology*, 2009.
 51. Sim HG, Telesca D, Culp SH, Lange PH, Ellis WJ, True LD, and **Lin DW**: Cancer to Total Prostate Volume Ratio Influences Pathologic Parameters and Biochemical Recurrence in Localized Prostate Cancer Treated by Radical Prostatectomy. Submitted to *European Urology*, 2009.
 52. Culp SH, Porter MP, **Lin DW**, True LD, and Weiss N: Incidence of Rare Prostate Cancer in the United States. Submitted to *Urology*, 2009.
 53. Wright JL, Lange PH, Ellis WJ, True LD, and **Lin DW**: Clinicopathologic Predictors of Tertiary Gleason Pattern 5 in Radical Prostatectomy Specimens. Submitted to *Urology*, 2009.
 54. **Lin DW**, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling DL, and Freedland SJ: Outcome Among Men with Pathological Gleason Sum 8-10

Prostate Cancer at the Time of Radical Prostatectomy: Results from the SEARCH Database. Submitted to *Urology*, 2009.

55. Morgan TM, Meng MV, Cowan JE, Weinberg VK, Carroll PR, and **Lin DW**: Adjusting the Definition of Biochemical Recurrence after Radical Prostatectomy by Clinicopathologic Risk Factors More Accurately Identifies Further PSA Progression. Submitted to *Journal the American Medical Association*, 2009.
56. **Lin DW**, Porter MP, and Montgomery RB: Treatment and survival outcomes in young men diagnosed with prostate cancer: a SEER database analysis. *Cancer*, in press, 2009.
57. Wright JL, Salinas CA, **Lin DW**, Kolb S, Koopmeiners J, Feng Z, and Stanford JL: Differences in prostate cancer-specific mortality between cases with Gleason 4+3 and Gleason 3+4 tumors: a population-based analysis. Submitted to *Journal of Urology*, 2009.
58. Wright JL, **Lin DW**, Kolb S, Feng Z, Koopmeiners J, Ostrander EA, and Stanford JL: CYP17 polymorphisms and prostate cancer mortality. Submitted to *Journal of Clinical Oncology*, 2009.
59. Wright JL, Risk MC, Hotaling J, and **Lin DW**: Effect of Collecting Duct Histology on Outcomes in Renal Cell Carcinoma. Submitted to *Journal of Urology*, 2009.

CHAPTERS OR REVIEW ARTICLES

1. **Lin DW** and Lange PH: Current Management of Testis Cancer. Practical Cases in Urology, AJ Wein, ed., American Urological Association, Inc., Office of Education, December 1999.
2. **Lin DW** and Lange PH: The Epidemiology and Natural History of Prostate Cancer. Prostatic Diseases, H Lepor, ed., W.B.Saunders Co., p 345-356, 2000.
3. **Lin DW**, Vessella RL, and Lange PH: Tumor Markers in Prostate Cancer. Prostate Cancer: Principles and Practice, P Carroll and A D'Amico, eds., W.B. Saunders Co., p. 305-312, 2002.
4. **Lin DW**, Eastham JA, and Scardino PT: Anatomical Radical Prostatectomy in the Management of Localized Prostate Cancer. Management of Prostate Cancer: Advances and Controversies. KB Cummings, ed., Marcel Dekker, Inc, 2006.
5. **Lin DW**, Pfitzenmaier J, Ellis WJ, Lange PH, and Vessella RL: Detection, Isolation, and Study of Disseminated Prostate Cancer Cells in the Peripheral Blood and Bone Marrow. Mechanisms of Metastasis. C Rinker-Schaeffer, ed, Humana Press, Inc, in press, 2006.
6. **Lin DW** and Brawer MK: PSA: Practical Applications and Future Prospects, Prostate Cancer: Principles and Practice, R Kirby, A Partin, M Feneley, JK Parsons, eds., Martin Dunitz Ltd, in press, 2006.
7. Wright JL, Higano CS, and **Lin DW**: Intermittent Androgen Deprivation: Clinical Experience and Practical Applications. Urologic Clinics of North America, J Smith ed, Saunders Inc, volume 33: 167-79, 2006.

8. Sim HG, Lange PH, and **Lin DW**: Role of Post-Chemotherapy Surgery in Germ Cell Tumors. Urologic Clinics of North America, J Sheinfeld ed, Saunders Inc, volume 34: 199-217, 2007.
9. Mostaghel EA, Montgomery RB, and **Lin DW**: The Basic Biochemistry and Molecular Events of Hormone Therapy. Current Urology Reports 8: 224-32, 2007.
10. Montgomery RB and **Lin DW**: Toxicities of Chemotherapy for Genitourinary Malignancies. Complications of Urologic Surgery: Prevention and Management, SS Taneja ed, Elsevier Inc, in press, 2009.
11. **Lin DW**: Beyond PSA: Utility of Novel Tumor Markers in the Setting of Elevated PSA. Urologic Oncology: Seminars and Original Investigations, in press, 2009.
12. Risk MC and **Lin DW**: New and Novel Markers in Prostate Cancer Detection: Current Urology Reports, in press, 2009.

EDITORIALS AND LETTERS

1. Lange PH and **Lin DW**: Does the Who and How of Surgery in Bladder Cancer Matter? *Journal of Clinical Oncology* 22:2762-4, 2004.
2. **Lin DW** and Lange PH: Is Pre-diagnosis PSA Velocity Predictive of the Risk of Death from Prostate Cancer Following Radical Prostatectomy? *Nature Clinical Practice Urology* 1: 66, 2004.
3. **Lin DW** and Lange PH: Urologic Oncology: Treatment of nonretroperitoneal residual germ cell tumor masses. *Urologic Oncology* 23: 439-40, 2005.
4. Salinas CA, Agalliu I, Stanford JL, and **Lin DW**: Statins and the Risk of Cancer. *JAMA* 295:2721, 2006.
5. **Lin DW** and Nelson PS: Microarray analysis and Tumor Classification. *N Engl J Med* 355: 960, 2006.
6. **Lin DW**: Does RPLND improve outcomes in men with intermediate-risk and high-risk germ cell tumors? *Nature Clinical Practice Urology* 4: 654-5, 2007.
7. **Lin DW**: Re: Prostate-specific Antigen Velocity in Men with Total Prostate-Specific Antigen Levels Less Than 4ng/ml. *Journal of Urology* 178: 2352-3, 2007.
8. **Lin DW**: Re: Prostate-specific antigen velocity and prostate cancer gleason grade and stage. *Urologic Oncology* 25: 529, 2007.
9. **Lin DW**: Re: Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. *Urologic Oncology* 25: 527-8, 2007.
10. **Lin DW**: Re: EPCA-2: A highly specific serum marker for prostate cancer. *Urologic Oncology* 25: 528, 2007.

11. **Lin DW:** Re:Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. *Urologic Oncology* 25: 528-9, 2007.
12. **Lin DW:** Re: Marked Gene Transcript Level Alterations Occur Early During Radical Prostatectomy. *Eur Urology* 53: 345-6, 2008.
13. **Lin DW:** Re: Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. *Urologic Oncology*, in press, 2008.
14. **Lin DW:** Re: Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. *Urologic Oncology*, in press, 2008.
15. **Lin DW:** Re: Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after prostatectomy. *Urologic Oncology*, in press, 2008.
16. **Lin DW:** Re: Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. *Journal of Urology*, in press, 2008.
17. **Lin DW:** Re: Adjuvant radiotherapy for patients with locally advanced prostate cancer – a new standard? *Urologic Oncology*, in press, 2008.

PUBLISHED ABSTRACTS

1. **Lin DW**, Colburn C, Cherrington AD: Insulin and Glucagon Independent Effects of Calcitonin Gene Related Peptide in the Conscious Dog. *Diabetes* 41(Suppl 1): 51A, 1992.
2. **Lin DW**, Buhler K, Whitney S, Lange PH, Vessella RL: Gene Expression in LuCap Prostate Cancer Xenograft Lines. *Proceedings of American Association for Cancer Research* 39: 367A, 1998.
3. Melchior S, **Lin DW**, Lange PH: Cystoprostatectomy and Continent Urinary Diversion for Locally Advanced Carcinoma of the Prostate. *Journal of Urology* 159(5 suppl): 337A, 1998.
4. **Lin DW**, Santucci R, Mayo ME, Lange PH, Mitchell MO: Urodynamic Evaluation of Gastric Neobladders After Urinary Diversion. *Journal of Urology* 159(5 suppl): 52A, 1998.
5. **Lin DW**, Kuhr CS, Marsh CL: Endoscopic Treatment of Bladder Outlet Obstruction in Men Following Pancreas Transplant. *Journal of Urology* 159(5 suppl): 116A, 1998.
6. **Lin DW**, Ellis WJ, True LD, Lange PH, Vessella RL: Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for Detection of Prostate Cancer Micrometastases in Pelvic Lymph Nodes (LN), Bone Marrow (BM), and Peripheral Blood (PB). *Journal of Urology* 161(4 suppl): 236A, 1999.

7. **Lin DW**, Ellis WJ, Lange PH, Vessella RL, Finlay JA, Rittenhouse HG, and Day J: Serum Human Glandular Kallikrein (hK2) in Metastatic Prostate Cancer. *Journal of Urology* 161(4 suppl): 510A, 1999.
8. Buhler KR, Quinn JE, Whitney SC, **Lin DW**, Ellis WJ, Corey E, Liu AY, True LD, Lange PH, Vessella RL, Macoska JA, and Bruchovsky N: The LuCap Series of Human Prostate Cancer Xenografts. *Journal of Urology* 161(4 suppl): 216A, 1999.
9. **Lin DW**, Herr HW, Dalbagni G: Value of Urethral Wash after Radical Cystectomy. *Journal of Urology* 165 (5 suppl): 715A, 2001.
10. **Lin DW**, Matsumura M, Kedishvili NY, True LD, and Nelson PS: Expression, Genomic Analysis, and Functional Studies of PSDR1, a Novel Short-Chain Dehydrogenase/Reductase Enzyme Expressed in the Prostate. *Journal of Urology* 169(4 suppl): 201A, 2003.
11. **Lin DW**, Wallner KE, and True LD: Inter-Observer Variability and Inaccuracy of Estimated Percentage of Prostate Cancer in Prostate Needle Biopsy Cores. *Journal of Urology* 169(4 suppl): 1143A, 2003.
12. **Lin DW**, Pfitzenmaier J, Ellis WJ, Arfman EW, Klein JR, Lange PH, and Vessella RL: Detection and Isolation of PSA Positive Epithelial Cells by Enrichment: Comparison to Standard PSA RT-PCR, Clinical Relevance, and Initial Characterization in Prostate Cancer Patients. *Journal of Urology* 179 (4 suppl): 837A, 2004.
13. Holcomb IN, Kinnunen M, Neal CL, Grove DI, Arfman EW, Lange PH, Hsu L, Delrow JJ, **Lin DW**, Trask BJ, and Vessella RL: Array Comparative Genomic Hybridization Analysis of Disseminated Epithelial Cells from the Blood and Bone Marrow of Men with Clinically Localized Prostate Cancer. *Journal of Urology* 173 (4 suppl): 220A, 2005.
14. **Lin DW**, Garnick MB, and Lange PH: Acute Effects of Initial LHRH Agonist Administration on Serum PSA and Testosterone in Eugonadal Men with Prostate Cancer. *Journal of Urology* 173 (4 suppl): 958A, 2005.
15. **Lin DW**, Ellis WJ, Lange PH, and True LD: Pelvic Lymphadenectomy in Radical Prostatectomy: Defining True Number of Nodes and Extent of Metastatic Prostate Cancer. *Journal of Urology* 173 (4 suppl): 1609A, 2005.
16. Porter MP and **Lin DW**: Trends in Renal Cancer Surgery in the United States and Patient and Provider Characteristics Associated with Partial Nephrectomy. *Journal of Urology* 175 (4 suppl): 225A, 2006.
17. **Lin DW**, Coleman IM, Hawley S, Dumpit R, Gifford D, Hung H, Knudsen BS, Kristal AR, and Nelson PS. The Influence of Surgical Manipulation on Prostate Gene Expression: Implications for Molecular Correlates of Treatment Effects and Disease Prognosis. *Journal of Urology* 175 (4 suppl): 809A, 2006.
18. Stephenson AJ, Pollack A, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Kupelian PA, Anscher MS, Michalski JM, Sandler HM, Zelefsky MJ,

- Forman JD, **Lin DW**, Kestin LL, Pistenmaa DA, Catton CN, Deweese TL, Valicenti RK, Kuban DA, Bianco FJ, and Fearn PA: A Nomogram to Predict the Outcome of Salvage Radiotherapy for Biochemical Recurrence Following Radical Prostatectomy. *Journal of Urology* 175 (4 suppl): 1192A, 2006.
19. Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, and **Lin DW**: Tertiary Gleason Pattern 5 in Gleason 7 Prostate Cancer Predicts Pathologic Parameters and Biochemical Recurrence. *Journal of Urology* 177 (4 suppl): 470A, 2007.
 20. Sim HG, Telesca D, Culp SH, Lange PH, Ellis WJ, True LD, and **Lin DW**: Cancer to Total Prostate Volume Ratio Influences Pathologic Parameters and Biochemical Recurrence in Localized Prostate Cancer Treated by Radical Prostatectomy. *Journal of Urology* 177 (4 suppl): 1029A, 2007.
 21. Black PC, Wright JL, Brown GA, Gomez JA, Porter MP, Kamat AM, Dinney CPN, and **Lin DW**: Differences in Survival Between Patients with Sarcomatoid Carcinoma, Carcinosarcoma, and Transitional Cell Carcinoma of the Bladder. *Journal of Urology* 177 (4 suppl): 1647A, 2007.
 22. Wright JL, **Lin DW**, and Porter MP: The Association Between Extent of Lymphadenectomy and Survival Among Patients with Lymph Node Metastases Undergoing Radical Cystectomy. *Journal of Urology* 177 (4 suppl): 1667A, 2007.
 23. Wright JL, Lange PH, Ellis WJ, True LD, and **Lin DW**: Clinicopathologic Predictors of Tertiary Gleason Pattern 5 in Radical Prostatectomy Specimens. *Journal of Urology* 179 (4 suppl): 155A, 2008.
 24. **Lin DW**, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling DL, and Freedland SJ: Outcome Among Men with Pathological Gleason Sum 8-10 Prostate Cancer at the Time of Radical Prostatectomy: Results from the SEARCH Database. *Journal of Urology* 179 (4 suppl): 426A, 2008.
 25. Morgan TM, Meng MV, Cowan JE, Weinberg VK, Carroll PR, and **Lin DW**: Adjusting the Definition of Biochemical Recurrence after Radical Prostatectomy by Clinicopathologic Risk Factors More Accurately Identifies Further PSA Progression. *Journal of Urology* 179 (4 suppl): 569A, 2008.
 26. Culp SH, Porter MP, **Lin DW**, True LD, and Weiss NS: Incidence and Survival of Rare Histologic Subtypes of Prostate Cancer Over a 30-yr Period. *Journal of Urology* 179 (4 suppl): 587A, 2008.
 27. Risk MC, Coleman I, Dumpit R, Gentleman RC, Kristal AR, Knudsen BS, Nelson PS, and **Lin DW**: Differential Gene Expression in Normal Prostate Epithelium of Men With and Without Prostate Cancer: Evidence for a Prostate Cancer Field Effect. *Journal of Urology* 179 (4 suppl): 1343A, 2008.
 28. Ginger VA, Zeliadt SB, and Lin DW: Incidence and Association of Skeletal Fractures with Duration of Androgen Deprivation Therapy Among Veterans. *Journal of Urology* 181 (4 suppl): 475A, 2009.

29. Wright JL, Hotaling J, Risk MC, and Lin DW: Effect of Collecting Duct Histology on Outcomes in Renal Cell Carcinoma. *Journal of Urology* 181 (4 suppl): 610A, 2009.
30. Lin DW, Marks LS, Morton RA, and Rodriguez D: Positive Fracture Reduction Trial of Toremifene 80 mg in Men on ADT Demonstrates Significant Fracture Risk in Untreated Placebo Group. *Journal of Urology* 181 (4 suppl): 639A, 2009.
31. Zeliadt SB, Ginger VA, Etzioni R, and Lin DW: Follow Up and Biopsy Patterns after Elevated Prostate Specific Antigen (PSA) Tests. *Journal of Urology* 181 (4 suppl): 2073A, 2009.
32. Koreckij TD, Morgan TM, Lange PH, Coleman I, Coleman R, Ellis WJ, Lin DW, Montgomery B, Lakely B, Morrissey C, and Vessella RL: Phenotypic Heterogeneity in Disseminated Prostate Cancer Tumor Cells: Implications in Epithelial to Mesenchymal Transition. *Journal of Urology* 181 (4 suppl): 2086A, 2009.
33. Morgan TM, Koreckij TD, Lin DW, Ellis WJ, Gallaher IS, Kinnunen M, Lakely B, Montgomery B, Lange PH, and Vessella RL: Effect of Androgen Deprivation Therapy on Disseminated Tumor Cells in Men with Prostate Cancer. *Journal of Urology* 181 (4 suppl): 2136A, 2009.
34. Wright JL, Lin DW, Kwon EM, Kolb S, Feng Z, Koopmeiners J, Ostrander EA, and Stanford JL: CYP17 Polymorphisms and Prostate Cancer Outcomes. *Journal of Urology* 181 (4 suppl): 2142A, 2009.

INVITED PRESENTATIONS AND CME

1. Pacific Northwest 2nd Annual Prostate Cancer Conference: “Genomics and Cancer: Profiling Gene Expression for Diagnosis, Prognosis and Treatment”, Seattle, WA, July 12, 2002.
2. 7th Annual National VA Oncology Symposium: “Localized Prostate Cancer: Surgical Management”, Alexandria, VA, October 3, 2002.
3. Veteran’s Affairs Seattle Puget Sound V-Tel Oncology Conference: “Surgical Outcomes and Future Directions in Localized Prostate Cancer”, Seattle, WA, March 25, 2003.
4. 5th Annual North Puget Sound Oncology Symposium: “Screening, Detection, and Staging of Prostate Cancer”, Mount Vernon, WA, October 23, 2003.
5. InterProstate SPORE Meeting: “Detection and Isolation of PSA Positive Epithelial Cells by Enrichment: Comparison to Standard RT-PCR, Clinical Relevance, and Initial Characterization in Prostate Cancer Patients”, Chicago, IL, January 27, 2004.
6. Auburn Regional Medical Center Grand Rounds: “Prostate Cancer Screening, Detection, and Treatment”, Auburn, WA, May 25, 2004.
7. 80th Annual Western Section American Urological Association Meeting: “Recent Advances in the Treatment of Hormone Refractory Prostate Cancer”, San Diego, CA, August 26, 2004.

8. UCSF Prostate Cancer Research Seminars: “Cyclooxygenase: Player or Spectator in Prostate Carcinogenesis”, San Francisco, CA, November 17, 2004.
9. Veteran’s Affairs Seattle Puget Sound GIMC Grand Rounds: “Localized Prostate Cancer: Screening, Detection, and Treatment”, Seattle, WA, March 29, 2005.
10. University of Washington Department of Family Medicine Grand Rounds: “Prostate Cancer 2005: An Update on Detection and Treatment of Prostate Cancer”, Seattle, WA, March 30, 2005.
11. Veteran’s Affairs Seattle Puget Sound Research and Development Symposium: “Cyclooxygenase: Player or Spectator in Prostate Carcinogenesis”, Seattle, WA, April 1, 2005.
12. American Society of Clinical Oncology 2005 Annual Meeting: Invited abstract discussant, “Disseminated Tumor Cells: Clinical Applications, Prognostic Significance, and Future Directions in Prostate Cancer Patients”, Orlando, FL, May 15, 2005.
13. American Urological Association 2005 Annual Meeting CME Course Director, “Treatment Strategies for Advanced Prostate Cancer in Younger Men”, San Antonio, TX, May 26, 2005.
14. 8th Annual Highlights of the American Urological Association 2005 National meeting, “AUA 2005: Prostate Cancer Highlights”, Washington University, St. Louis, MO, July 25, 2005.
15. 2nd Annual Phoenix Multidisciplinary Cancer Symposium, “Contemporary Treatment of Prostate Cancer 2005”, Phoenix, AZ, October 8, 2005.
16. Seattle Cancer Care Alliance Outreach Symposium, “Management of Prostate Cancer 2005”, Mount Vernon, WA, October 25, 2005.
17. 2006 Prostate Cancer Symposium, “Influence of Surgical Manipulation on Prostate Gene Expression: Implications for Molecular Correlates of Treatment Effects and Disease Prognosis”, San Francisco, CA, February 26, 2006.
18. Male Genitourinary Health Update, Spokane County Medical Society, “Prostate Cancer Prevention: Myth or Reality?”, Spokane, WA, March 14, 2006.
19. Skagit Valley Cancer Center Symposium, “Prostate Cancer: Diagnosis and Treatment”, Mount Vernon, WA, March 15, 2006.
20. Fred Hutchinson Cancer Research Center Clinical Oncology Grand Rounds, “High-Risk Prostate Cancer: Treatment Controversies and the Multidisciplinary Approach”, Seattle, WA, May 2, 2006.
21. American Urological Association 2006 Annual Meeting CME Course Director, “Clinical Scenarios and Treatment Strategies for Advanced Prostate Cancer in Younger Men”, Atlanta, GA, May 22, 2006.

22. 34th Annual Advances in Family Practice and Primary Care, “Prostate Cancer Screening”, Seattle, WA, September 14, 2006.
23. Evergreen Hospital Grand Rounds, “Prostate Cancer Update 2006”, Kirkland, WA, October 13, 2006.
24. Northwest Urological Society Annual Meeting, “Adjuvant Chemohormonal Therapy in High Risk Prostate Cancer: a Point-Counterpoint Debate”, Spokane, WA, December 8, 2006.
25. VA R&D Research Colloquium, “Progress and Promise in Prostate Cancer Research”, Seattle, WA, January 17, 2007.
26. American Association of Pediatric Ophthalmology and Strabismus Annual Meeting, “Everything You Want To Know About Prostate Cancer in 2007”, Seattle, WA, April 13, 2007.
27. Providence Saint Joseph Medical Center Grand Rounds, “Screening and Diagnosis of Prostate Cancer”, Burbank, CA, April 24, 2007.
28. American Urological Association 2007 Annual Meeting CME Course Director, “Clinical Scenarios and Treatment Strategies for Advanced Prostate Cancer in Younger Men”, Anaheim, CA, May 20, 2007.
29. Men’s Health Update CME Course, “Prostate Anatomy and Evaluation of Lower Urinary Tract Symptoms”, Seattle, WA, Aug 21, 2007.
30. Men’s Health Update CME Course, “Prostate Carcinogenesis”, Seattle, WA, Aug 22, 2007.
31. Seattle Cancer Care Alliance Outreach Symposium, “Diagnosis and Management of Clinically Localized Prostate Cancer 2007”, Great Falls, MT, September 18, 2007.
32. 23rd Annual Urological Research Society Meeting, “Differential Gene Expression in Normal Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect”, Napa, CA, October 26, 2007.
33. 83rd Annual Western Section American Urological Association Meeting: “Adjuvant Treatment Strategies for High-Risk Post-Prostatectomy Prostate Cancer: Emerging Data and New Directions”, Scottsdale, AZ, October 30, 2007.
34. Urology Research Forum, Charles University: “Management of High Risk Prostate Cancer”, Prague, Czechoslovakia, March 17, 2008.
35. Society of Urologic Oncology Plenary Session, American Urological Association 2008 Annual Meeting, “Beyond PSA: Utility of Novel Tumor Markers in the Setting of Elevated PSA”. Orlando, FL, May 17, 2008.
36. AUA Research Forum, American Urological Association 2008 Annual Meeting, “The Effects of Sulforaphane on Normal Human Prostate Cells: Mechanisms of Cancer Prevention”. Orlando, FL, May 18, 2008.

37. American Urological Association 2008 Annual Meeting CME Course Faculty, "PSA Best Practice Guidelines", Update on Cancer-Related AUA Guidelines: Preparation for Recertification. Orlando, FL, May 18, 2008.
38. American Urological Association 2008 Annual Meeting CME Course Faculty, "Non-Muscle Invasive Bladder Cancer: AUA Management Guidelines", Update on Cancer-Related AUA Guidelines: Preparation for Recertification. Orlando, FL, May 18, 2008.
39. Roswell Park Surgical Grand Rounds, "Adjuvant Treatment Strategies for High-Risk Post-Prostatectomy Prostate Cancer: Emerging Data and New Directions". Roswell Park Cancer Institute, Buffalo, NY, June 11, 2008.
40. Scott Department of Urology Grand Rounds, "Risk Stratification, Mechanisms of Recurrence, and Adjuvant Treatment Strategies for High-Risk Post-Prostatectomy Prostate Cancer". Baylor University School of Medicine, Houston, TX, June 25, 2008.
41. 36th Annual Advances in Family Practice and Primary Care, "Prostate Cancer Screening and Rationale For/Against Early Detection of Localized Prostate Cancer", Seattle, WA, September 10, 2008.
42. Puget Sound Health Care System Prostate Cancer Awareness Month Symposium, "Prostate Cancer Screening and Evaluation and Treatment of Newly Diagnosed Prostate Cancer", Seattle, WA, September 12, 2008.
43. Pacific NW Prostate Cancer SPORE External Advisory Board Symposium, "The Effects of Sulforaphane on Normal Human Prostate Cells: Mechanisms of Cancer Prevention and Rationale for Clinical Trial", Seattle, WA, November 17, 2008.
44. Moffitt Cancer Center Advanced Prostate Cancer Collaboration, "Beyond PSA: Utility of Novel Prostate Cancer Markers in Advanced Disease", Tampa, FL, November 24, 2008.
45. Albany VA Grand Rounds, "Progress and Promise in Prostate Cancer", Albany, NY, February 24, 2009.
46. 3rd Annual John R. Murren Oncology Symposium, "The Role of Peri-Operative Chemotherapy in High-Risk Prostate Cancer: PUNCH and VA Surgical Trials", Las Vegas, NV, March 27, 2009.

ABSTRACT PRESENTATIONS

1. **Lin DW**, Bush WH, Mayo ME: Efficacy of Acucise Incision on Uretero-Enteral Strictures. Presented to the Northwest Urologic Association, Portland, OR, December 9, 1996.
2. **Lin DW**, Ellis WJ: Transurethral Needle Ablation of the Prostate for Treatment of Benign Prostatic Hyperplasia: the University of Washington Experience. Presented to Northwest Urological Society, Seattle, WA, December 6, 1997.
3. **Lin DW**, Krieger JN: Primary Penile Lymphoma Treated With Surgical Excision. Presented to Northwest Urological Society, Seattle, WA, December 6, 1997.

4. **Lin DW**, Kuhr CS, Marsh CL: Endoscopic Treatment of Bladder Outlet Obstruction in Men Following Pancreas Transplant. Presented to the Pacific Northwest Transplant and Vascular Society, April 15, 1998.
5. **Lin DW**, Santucci R, Mayo ME, Lange PH, Mitchell MO: Urodynamic Evaluation of Gastric Neobladders After Urinary Diversion. Presented to American Urological Association, May 31, 1998.
6. **Lin DW**, Kuhr CS, Marsh CL: Endoscopic Treatment of Bladder Outlet Obstruction in Men Following Pancreas Transplant. Presented to American Urological Association, June 1, 1998.
7. **Lin DW**, Ellis WJ, Lange PH: Salvage Cystoprostatectomy for Treatment of Recurrent Prostate Cancer After Radiation Treatment. Presented to Western Section American Urological Association, October 25, 1998.
8. **Lin DW**, Ellis WJ, Arfman EW, Sohn A, Corey E, Lange PH, Vessella RL: Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) in Bone Marrow Aspirates Following Radical Prostatectomy with Extended Follow-up. Presented to Western Section American Urological Association, October 25, 1998.
9. **Lin DW**, Ellis WJ: Transurethral Needle Ablation of the Prostate for Treatment of Benign Prostatic Hyperplasia: the University of Washington Experience. Presented to Western Section American Urological Association, October 25, 1998.
10. **Lin DW**, Ellis WJ, True LD, Felise DG, Oswin MM, Vessella RL, Lange PH: Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for Detection of Prostate Cancer Micrometastases in Pelvic Lymph Nodes (LN), Bone Marrow (BM), and Peripheral Blood (PB). Presented to Western Section American Urological Association, October 27, 1998.
11. **Lin DW**, Buhler K, Whitney S, Lange PH, Vessella RL: Gene Expression in LuCap Prostate Cancer Xenograft Lines. Presented to Western Section American Urological Association, October 27, 1998.
12. **Lin DW**, Noteboom JL, Ellis WJ, Blumenstein B, Lange PH, Vessella RL: Serum Percent Free Prostate-Specific Antigen (f-PSA) in Metastatic Prostate Cancer. Presented to Western Section American Urological Association, October 27, 1998.
13. **Lin DW**, Ellis WJ, Lange PH, Vessella RL: "Unexplained Elevated Prostate-Specific Antigen: Diagnostic Approach and Unique Clinical Considerations. Presented to Northwest Urological Society, December 4, 1998.
14. **Lin DW**, Ellis WJ, True LD, Lange PH, Vessella RL: Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for Detection of Prostate Cancer Micrometastases in Pelvic Lymph Nodes (LN), Bone Marrow (BM), and Peripheral Blood (PB). Presented to Northwest Urological Society, December 5, 1998.

15. **Lin DW**, Ellis WJ, True LD, Lange PH, Vessella RL: Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for Detection of Prostate Cancer Micrometastases in Pelvic Lymph Nodes (LN), Bone Marrow (BM), and Peripheral Blood (PB). Presented to American Urological Association, May 4, 1999.
16. **Lin DW**, Ellis WJ, Lange PH, Vessella RL, Finlay JA, Rittenhouse HG, and Day J: Serum Human Glandular Kallikrein (hK2) in Metastatic Prostate Cancer. Presented to American Urological Association, May 2, 1999.
17. **Lin DW**, Ellis WJ, Buhler K, Quinn J, Vessella RL, Lange PH: The LuCaP Prostate Cancer Xenografts: Establishment and Characterization. Presented to Northwest Urological Society, December 3, 1999.
18. **Lin DW**, Kuhr CS, Marsh CL, Ellis WJ, Thompson JA, Lange PH: Cytoreductive Surgery for Metastatic Renal Cell Carcinoma: Operative Results and Impact on Adjuvant Therapy. Presented to Northwest Urological Society, December 4, 1999.
19. **Lin DW**, Ellis WJ, Buhler K, Quinn J, Vessella RL, Lange PH: The LuCaP Prostate Cancer Xenografts: Establishment and Characterization. Presented to Society for University Urologic Residents, Atlanta, GA, May 25, 2000.
20. **Lin DW**, Herr HW, Dalbagni G: Value of Urethral Wash after Radical Cystectomy. Presented to American Urological Association, Anaheim, CA, June 4, 2001.
21. **Lin DW**, Matsumura M, Kedishvili NY, True LD, Nelson PS: Expression, Genomic Analysis, and Functional Studies of PSDR1, a Novel Short-Chain Dehydrogenase/Reductase Enzyme Expressed in the Prostate. Presented to American Urological Association, Chicago, IL, April 27, 2003.
22. **Lin DW**, Wallner KE, True LD: Inter-Observer Variability and Inaccuracy of Estimated Percentage of Prostate Cancer in Prostate Needle Biopsy Cores. Presented to American Urological Association, Chicago, IL, April 29, 2003.
23. **Lin DW**, Pfitzenmaier J, Ellis WJ, Arfman EW, Klein JR, Lange PH, and Vessella RL: Detection and Isolation of PSA Positive Epithelial Cells by Enrichment: Comparison to Standard PSA RT-PCR, Clinical Relevance, and Initial Characterization in Prostate Cancer Patients. Presented to American Urological Association, San Francisco, CA, May 10, 2004.
24. **Lin DW**, Ellis WJ, Kinnunen M, Arfman EW, Klein JR, Lange PH, and Vessella RL: Detection and Isolation of PSA Positive Epithelial Cells by Enrichment: Clinical Relevance, and Initial Characterization in Prostate Cancer Patients. Presented to 12th SPORE Investigators Workshop, Washington, DC, July 12, 2004.
25. Montgomery B, **Lin DW**, Ryan C, Garzotto M, and Beer TM: Diethylstilbestrol and docetaxel: a phase II study in patients with metastatic androgen independent prostate cancer. Presented to Multidisciplinary Prostate Cancer Symposium, Orlando, FL, February 19, 2005.

26. Holcomb IN, Kinnunen M, Neal CL, Grove DI, Arfman EW, Lange PH, Hsu L, Delrow JJ, **Lin DW**, Trask BJ, and Vessella RL: Array Comparative Genomic Hybridization Analysis of Disseminated Epithelial Cells from the Blood and Bone Marrow of Men with Clinically Localized Prostate Cancer. Presented to American Urological Association, San Antonio, TX, May 22, 2005.
27. **Lin DW**, Garnick MB, and Lange PH: Acute Effects of Initial LHRH Agonist Administration on Serum PSA and Testosterone in Eugonadal Men with Prostate Cancer. Presented to American Urological Association, San Antonio, TX, May 23, 2005.
28. **Lin DW**, Ellis WJ, Lange PH, and True LD: Pelvic Lymphadenectomy in Radical Prostatectomy: Defining True Number of Nodes and Extent of Metastatic Prostate Cancer. Presented to American Urological Association, San Antonio, TX, May 25, 2005.
29. **Lin DW**, Coleman I, Hawley S, Dumpit R, Gifford D, Kezele P, and Nelson PS: Effect of Surgical Manipulation on Tissue Gene Expression: Impact on Endpoint Analyses. Presented to 13th SPORE Investigators Workshop, Washington, DC, July 11, 2005.
30. **Lin DW**, Coleman I, Hawley S, Dumpit R, Gifford D, Kezele P, Hung H, Knudsen BS, Kristal AR, and Nelson PS: Influence of Surgical Manipulation on Prostate Gene Expression: Implications for Molecular Correlates of Treatment Effects and Disease Prognosis. Presented to 6th Annual Society of Urologic Oncology Conference, Bethesda, MD, December 3, 2005.
31. Montgomery RB, Porter M, and **Lin DW**: Treatment patterns for young men with prostate cancer: a SEER database analysis. Presented to 2006 Multidisciplinary Prostate Symposium, San Francisco, CA, February 25, 2006.
32. **Lin DW**, Coleman IM, Hawley S, Dumpit R, Gifford D, Hung H, Knudsen BS, Kristal AR, and Nelson PS: The Influence of Surgical Manipulation on Prostate Gene Expression: Implications for Molecular Correlates of Treatment Effects and Disease Prognosis. Presented to American Urological Association, Atlanta, GA, May 22, 2006.
33. Wright JL, **Lin DW**, Cowan JE, DuChane J, Carroll PR, and Litwin MS: Quality of Life in Young Men after Radical Prostatectomy: Results from the CAPSURE Registry. Presented to American Society of Clinical Oncology, 2006 Annual Meeting, Atlanta, GA, June 5, 2006.
34. **Lin DW**, Neuhouser ML, Schenk JM, Coleman IM, Hawley S, Gifford D, Hung H, Knudsen BS, Nelson PS, and Kristal AR: Global gene expression changes in human prostate tissue in response to dietary intervention. Presented to Western Section American Urological Association, Maui, HI, October 26, 2006.
35. Wright JL, Lange PH, Ellis WJ, True LD, and **Lin DW**: Clinicopathologic Predictors of Tertiary Gleason Pattern 5 in Radical Prostatectomy Specimens. Presented to American Urological Association 2008 Annual Meeting, Orlando, FL, May 18, 2008.

36. **Lin DW**, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling DL, and Freedland SJ: Outcome Among Men with Pathological Gleason Sum 8-10 Prostate Cancer at the Time of Radical Prostatectomy: Results from the SEARCH Database. Presented to American Urological Association 2008 Annual Meeting, Orlando, FL, May 18, 2008.

CLINICAL TRIALS

1. Hormones, Nutrients, and Gene Expression in Prostate Tissue, 2003-present
Sponsor: Intramural
Role: Principal Investigator
2. Selenium and Vitamin E Cancer Prevention Trial (SELECT), 2003-present
Sponsor: SWOG
Role: Principal Investigator
3. Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), 2003-present
Sponsor: UCSF Urology
Role: Principal Investigator
4. Brachytherapy Tissue Repository & Registry, 2004-present
Sponsor: Intramural
Role: Principal Investigator
5. Prevention of Lung Function Decline with Vitamin E and Selenium: Respiratory Ancillary Study to SELECT, 2004-present
Sponsor: SWOG
Role: Principal Investigator
6. In Vivo Molecular Effects of Aspirin on Prostate Tissue, 2005-present
Sponsor: NIH/NIDDK
Role: Principal Investigator
7. Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer: A Pilot Study, 2005 – 2007
Sponsor: Intramural
Role: Co-Investigator
8. A Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Toremifine Citrate for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy, 2004 – 2008
Sponsor: GTX, Inc
Role: Principal Investigator
9. TAX 3501: Immediate versus Deferred Treatment with Androgen Ablation with or without Docetaxel in High-Risk Prostate Cancer after Prostatectomy, 2005 – 2007
Sponsor: Sanofi-Aventis
Role: Principal Investigator
10. Testosterone Replacement and Dutasteride Effectiveness (TRADE), 2005-present

Sponsor: Glaxo Smith Kline and Solvay Pharmaceuticals
Role: Sub-Investigator

11. Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer, 2007 – present
Sponsor: NIH (SPORE), GlaxoSmithKline, and AstraZeneca
Role: Co-investigator
12. Prostate Active Surveillance Study (PASS), 2008 – present
Sponsor: Canary Foundation/EDRN
Role: Principal Investigator
13. Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer, 2008 – present
Sponsor: NIH (SPORE) and ImClone Systems
Role: Co-investigator